Hippo signaling pathway and colorectal cancer

Abstract

Abstract:Hippo signaling pathway plays a significant role in the development of colorectal cancer, and acts as an important regulatory pathway which regulates cell proliferation and cell differentiation. Multiple proteins and genes in Hippo signaling pathway, especially the downstream YAP protein, play important roles in the occurrence, metastasis, drug resistance and recurrence of colorectal cancer. YAP and other related genes can be used as targeted markers for predicting drug resistance to colorectal cancer. Hippo signaling pathway gene network can be used as targeted therapy or combination therapy, thus providing new ideas for the treatment of colorectal cancer.

Key words:Colorectal neoplasms,Molecular targeted therapy,Hippo signaling pathway,YAP protein

Gu Sijia, Sun Guozhuang, Qiao Dawei, Zhong Yi, Kong Guimei, Bu Ping. Hippo signaling pathway and colorectal cancer[J]. Journal of International Oncology, 2019, 46(5): 299-302.

References

［1］ Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492. ［2］ Zhang L, Cao F, Zhang G, et al. Trends in and predictions of colorectal cancer incidence and mortality in China from 1990 to 2025［R］. Front Oncol, 2019, 9: 98. DOI: 10.3389/fonc.2019.00098. ［3］ Plouffe SW, Lin KC, Moore JL, et al. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell［J］. J Biol Chem, 2018, 293(28): 11230-11240. DOI: 10.1074/jbc.RA118.002715. ［4］ Frankel NW, Lim WA. Building a stable relationship: Ensuring homeostasis among cell types within a tissue［J］. Cell, 2018, 172(4): 638-640. DOI: 10.1016/j.cell.2018.01.024. ［5］ Lu L, Finegold MJ, Johnson RL. Hippo pathway coactivators Yap and Taz are required to coordinate mammalian liver regeneration［J］. Exp Mol Med, 2018, 50(1): e423. DOI: 10.1038/emm.2017.205. ［6］ Moon S, Yeon Park S, Woo Park H. Regulation of the Hippo pathway in cancer biology［J］. Cell Mol Life Sci, 2018, 75(13): 2303-2319. DOI: 10.1007/s00018-018-2804-1. ［7］ Fang L, Teng H, Wang Y, et al. SET1Amediated monomethylation at K342 regulates YAP activation by blocking its nuclear export and promotes tumorigenesis［J］. Cancer Cell, 2018, 34(1): 103-118. DOI: 10.1016/j.ccell.2018.06.002. ［8］ Wang F, Wang B, Long J, et al. Identification of candidate target genes for endometrial cancer, such as ANO1, using weighted gene co expression network analysis［J］. Exp Ther Med, 2019, 17(1): 298-306. DOI: 10.3892/etm.2018.6965. ［9］ Dehghanian F, Hojati Z, Hosseinkhan N, et al. Reconstruction of the genomescale coexpression network for the Hippo signaling pathway in colorectal cancer［J］. Comput Biol Med, 2018, 99: 76-84. DOI: 10.1016/j.compbiomed.2018.05.023. ［10］ Gibault F, Sturbaut M, Bailly F, et al. Targeting transcriptional enhanced associate domains (TEADs)［J］. J Med Chem, 2018, 61(12): 5057-5072. DOI: 10.1021/acs.jmedchem.7b00879. ［11］ Wang X, Sun D, Tai J, et al. TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway［J］. J Exp Clin Cancer Res, 2018, 37(1): 27. DOI: 10.1186/s13046-018-0683-9. ［12］ Ou C, Sun Z, Li S, et al. Dual roles of yesassociated protein (YAP) in colorectal cancer［J］. Oncotarget, 2017, 8(43): 75727-75741. DOI: 10.18632/oncotarget.20155. ［13］ Poma AM, Torregrossa L, Bruno R, et al. Hippo pathway affects survival of cancer patients: extensive analysis of TCGA data and review of literature［J］. Sci Rep, 2018, 8(1): 10623. DOI: 10.1038/s41598-018-28928-3. ［14］ Zhang S, Wei Q, Yang Y, et al. Loss of Yesassociated protein represents an aggressive subtype of colorectal cancer［J］. J Cancer, 2019, 10(3): 689-696. DOI: 10.7150/jca.28333. ［15］ Zhou Z, Zhang HS, Zhang ZG, et al. Loss of HACE1 promotes colorectal cancer cell migration via upregulation of YAP1［J］. J Cell Physiol, 2019, 234(6): 9663-9672. DOI: 10.1002/jcp.27653. ［16］ Pan Y, Tong JHM, Lung RWM, et al. RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer［J］. Mol Cancer, 2018, 17(1): 102. DOI: 10.1186/s12943-018-0853-6. ［17］ Wang Q, Gao X, Yu T, et al. REGγ controls Hippo signaling and reciprocal NF-κB YAP regulation to promote colon cancer［J］. Clin Cancer Res, 2018, 24(8): 2015-2025. DOI: 10.1158/1078-0432.CCR-17-2986. ［18］ Huyghe JR, Bien SA, Harrison TA, et al. Discovery of common and rare genetic risk variants for colorectal cancer［J］. Nat Genet, 2019, 51(1): 76-87. DOI: 10.1038/s41588-018-0286-6. ［19］ Yang C, Xu W, Meng X, et al. SCC-S2 facilitates tumor proliferation and invasion via activating Wnt signaling and depressing Hippo signaling in colorectal cancer cells and predicts poor prognosis of patients［J］. J Histochem Cytochem, 2019, 67(1): 65-75. DOI: 10.1369/0022155418799957. ［20］ Yao P, Li Y, Shen W, et al. ANKHD1 silencing suppresses the proliferation, migration and invasion of CRC cells by inhibiting YAP1-induced activation of EMT［J］. Am J Cancer Res, 2018, 8(11): 2311-2324. ［21］ Eskandari E, Mahjoubi F, Motalebzadeh J. An integrated study on TFs and miRNAs in colorectal cancer metastasis and evaluation of three co-regulated candidate genes as prognostic markers［J］. Gene, 2018, 679: 150-159. DOI: 10.1016/j.gene.2018.09.003. ［22］ Song R, Gu D, Zhang L, et al. Functional significance of Hippo/YAP signaling for drug resistance in colorectal cancer［J］. Mol Carcinog, 2018, 57(11): 1608-1615. DOI: 10.1002/mc.22883. ［23］ Liu BS, Xia HW, Zhou S, et al. Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells［J］. Oncol Rep, 2018, 40(4): 2171-2182. DOI: 10.3892/or.2018.6630. ［24］ Yu M, Luo Y, Cong Z, et al. MicroRNA-590-5p inhibits intestinal inflammation by targeting YAP［J］. J Crohns Colitis, 2018, 12(8): 993-1004. DOI: 10.1093/ecco-jcc/jjy046. ［25］ Shen X, Sun X, Sun B, et al. ARRDC3 suppresses colorectal cancer progression through destabilizing the oncoprotein YAP［J］. FEBS Lett, 2018, 592(4): 599-609. DOI: 10.1002/1873-3468.12986. ［26］ Greenhough A, Bagley C, Heesom KJ, et al. Cancer cell adaptation to hypoxia involves a HIF-GPRC5A-YAP axis［J］. EMBO Mol Med, 2018, 10(11). pii: e8699. DOI: 10.15252/emmm.201708699. ［27］ Li Q, Qi F, Meng X, et al. Mst1 regulates colorectal cancer stress response via inhibiting Bnip3related mitophagy by activation of JNK/p53 pathway［J］. Cell Biol Toxicol, 2018, 34(4): 263-277. DOI: 10.1007/s10565-017-9417-6. ［28］ Deng X, Fang L. VGLL4 is a transcriptional cofactor acting as a novel tumor suppressor via interacting with TEADs［J］. Am J Cancer Res, 2018, 8(6): 932-943. ［29］ Toden S, Ravindranathan P, Gu J, et al. Oligomeric proanthocyanidins (OPCs) target cancer stemlike cells and suppress tumor organoid formation in colorectal cancer［J］. Sci Rep, 2018, 8(1): 3335. DOI: 10.1038/s41598-018-21478-8. ［30］ Unterer B, Wiesmann V, Gunasekaran M, et al. IFN-γ-response mediator GBP-1 represses human cell proliferation by inhibiting the Hippo signaling transcription factor TEAD［J］. Biochem J, 2018, 475(18): 2955-2967. DOI: 10.1042/BCJ20180123. ［31］ Theodosakis N, Langdon CG, Micevic G, et al. Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment resistant melanoma, colorectal, and lung cancer［J］. Pigment Cell Melanoma Res, 2019, 32(2): 292-302. DOI: 10.1111/pcmr.12742. ［32］ Qian J, Fang D, Lu H, et al. Tanshinone ⅡA promotes IL2-mediated SW480 colorectal cancer cell apoptosis by triggering INF2-related mitochondrial fission and activating the Mst1Hippo pathway［J］. Biomed Pharmacother, 2018, 108: 1658-1669. DOI: 10.1016/j.biopha.2018.09.170.

[1]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[5]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.Progress of ferroptosis-related mechanisms in osteosarcoma[J]. Journal of International Oncology, 2024, 51(5): 308-311.
[6]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[7]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[8]	Huang Hui, Ding Jianghua.Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma[J]. Journal of International Oncology, 2023, 50(9): 569-573.
[9]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong.Expression and clinical significance of ASB6 in colorectal cancer tissues[J]. Journal of International Oncology, 2023, 50(8): 470-474.
[10]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[11]	Liu Li, Zhu Siqi, Sun Mengying, He Jingdong.Progress of PARP inhibitors in targeted therapy of small cell lung cancer[J]. Journal of International Oncology, 2023, 50(6): 368-372.
[12]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing.Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer[J]. Journal of International Oncology, 2023, 50(5): 268-273.
[13]	Liu Bohan, Huang Junxing.Research progress of solute carriers related genes in malignant tumors[J]. Journal of International Oncology, 2023, 50(5): 280-284.
[14]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240.
[15]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun.Construction of postoperative prognosis model for patients with colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 157-163.